Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pentetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.46 |
| ▸ | CA4 known ✓ | P22748 | 8/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.37 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL65157 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL9564091 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL7190674 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL342065 | 0.97 | KDM4E (0.81) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL194754 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8091381 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5273812 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL8372011 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL570988 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL3394139 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173283-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT | SBI PHARMACEUTICALS CO., LTD. (JP) | 2024-05-30 | — | — | US | claimed |
| EP-3508200-B1 | AQUEOUS FORMULATION CONTAINING 5-AMINOLEVULINIC ACID OR THE LIKE | SBI PHARMACEUTICALS CO LTD (JP) | 2024-04-10 | — | — | EP | claimed |
| EP-4316480-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT | Kyushu University, National University Corporation (JP) | 2024-02-07 | — | — | EP | claimed |
| EP-3168296-B1 | AGENT FOR IMPROVING NORMAL DEVELOPMENT RATE OF FERTILIZED EGGS | SBI PHARMACEUTICALS CO LTD (JP) | 2020-09-09 | — | — | EP | claimed |
| CN-111559935-A | Weak-acid solid water-soluble fertilizer for improving alkaline soil | 上海润绣农业科技有限公司 | 2020-08-21 | — | — | CN | claimed |
| US-10675242-B2 | Aqueous formulation containing 5-aminolevulinic acid or the like | SBI PHARMACEUTICALS, CO., LTD. (JP) | 2020-06-09 | — | — | US | claimed |
| CN-104487066-B | Prophylactic and/or therapeutic agent for radiation damage | 国立大学法人东京大学 | 2020-06-09 | — | — | CN | claimed |
| EP-2767278-B1 | ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN | SBI PHARMACEUTICALS CO LTD (JP) | 2019-11-06 | — | — | EP | claimed |
| EP-2875812-B1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR RADIATION DAMAGE | UNIV TOKYO (JP) | 2019-09-04 | — | — | EP | claimed |
| EP-3508200-A1 | AQUEOUS FORMULATION CONTAINING 5-AMINOLEVULINIC ACID OR THE LIKE | SBI Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | claimed |
| EP-2340821-A1 | PROPHYLACTIC/AMELIORATING AGENT FOR ADULT DISEASES COMPRISING 5-AMINOLEVULINIC ACID, DERIVATIVE OF 5-AMINOLEVULINIC ACID, OR SALT OF 5-AMINOLEVULINIC ACID OR THE DERIVATIVE OF 5-AMINOLEVULINIC ACID AS ACTIVE INGREDIENT | SBI ALApromo Co., Ltd. (JP) | 2011-07-06 | — | — | EP | claimed |
| EP-2305237-A1 | THERAPEUTIC AGENT FOR MALE STERILITY | SBI ALApromo Co., Ltd. (JP) | 2011-04-06 | — | — | EP | claimed |
| US-20110065787-A1 | THERAPEUTIC AGENT FOR MALE STERILITY | SBI ALApromo., Ltd. | 2011-03-17 | — | — | US | claimed |
| US-20110060042-A1 | EXTERNAL PREPARATION FOR SKIN | SBI ALAPROMO CO., LTD. (JP) | 2011-03-10 | — | — | US | claimed |
| US-20100120916-A1 | THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASES | SBI ALAPROMO CO., LTD. (JP) | 2010-05-13 | — | — | US | claimed |
| EP-2135613-A1 | REMEDY AND DIAGNOSTIC FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASE | SBI ALApromo CO., LTD. (JP) | 2009-12-23 | — | — | EP | claimed |
| US-20090130227-A1 | EXTERNAL PREPARATION FOR SKIN | SBI ALAPROMO CO., LTD. (JP) | 2009-05-21 | — | — | US | claimed |
| EP-1878421-A1 | EXTERNAL PREPARATION FOR SKIN | COSMO OIL CO., LTD (JP) | 2008-01-16 | — | — | EP | claimed |
| US-20070249721-A1 | Hair Restorer | COSMO ALA CO., LTD. (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1743621-A1 | HAIR RESTORER | Ito, Yoshiyasu (JP) | 2007-01-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675242-B2 | Aqueous formulation containing 5-aminolevulinic acid or the like | ALAD, AAAS, SLC7A5 | ACE 1437/4885CA4 1402/4885CA2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.